Radiopharmaceutical conjugates (RDCs) represent an innovative class of precision tumor-targeting drugs. Their structure consists of four core components: a targeting ligand (which specifically recognizes tumor cells), a linker (connecting the targeting ligand to the chelator), a chelator (which stably binds the nuclide), and a radionuclide (which enables diagnosis or therapy). RDCs can directionally deliver radionuclides to tumor tissues, thereby achieving precise diagnosis and treatment of tumors.

By leveraging intraoperative 3D imaging technology innovation as a breakthrough, it supports the development of digital and intelligent surgical techniques. First-Imaging Medical continuously builds a closed-loop solution of "Equipment + AI + Ecosystem", thereby facilitating the leapfrog upgrade of surgical procedures from "experience-driven" to "intelligence-driven".

This financing not only set a new record for Cascade in terms of single-round funding but also highlighted the capital market's recognition of the R&D team's "strong technical expertise and differentiated pipeline" in the fields of nuclear receptors and GPCR.

Transcend Vivoscope's competitive moat is built upon its comprehensive, groundbreaking advancements in "miniaturized multi-photon imaging," spanning from technological breakthroughs and core components to complete system integration.

Preliminary statistics from VCBeat tracked 13 financing events in China's healthcare sector between February 2 and 6, 2026 (excluding IPOs and private placements). The period was led by Angitia Biopharmaceuticals' USD 130 million Series D round, followed by Deep Intelligent Pharma's USD 60 million round.

ICE Intelligent Healthcare's 2D ICE product received regulatory approval in February 2025 and has since participated in centralized procurement processes across various regions. This marks ICE Intelligent Healthcare's first product to obtain a Class III medical device registration certificate. Thanks to its superior image quality, the product has gained widespread recognition from medical experts.

Over the past year of market expansion, industrial clients now account for approximately 40% of Huixin Lifetech's revenue, with consumables sales growing rapidly, reflecting the sustained release of industrial demand. Huixin Lifetech's overall revenue continues to grow at a high pace, with downstream industries demonstrating accelerating positive momentum.

Distinguished by core advantages including true registration-free operation, unobstructed workflow, interference resistance, rapid procedure times, a short learning curve, and a compact footprint, the system is further enhanced by Yangshan Medical's proprietary AI technology platform to assist surgeons in performing oral surgeries with greater efficiency and precision.

Historically, this therapeutic area has been dominated by single-target agents such as SGLT2 inhibitors and Angiotensin II Receptor Blockers (ARBs). Although these drugs hold significant market share, intensifying homogeneity and competition have followed patent expirations and the entry of generic alternatives. Against this backdrop, the scarcity of innovative assets with unique mechanisms of action has become prominent. The dual-target design of MT1013 aligns precisely with the industry's demand for "differentiated innovation," which is central to the rationale for its substantial licensing fee.

Pumecitinib is a fully proprietary JAK1/2 inhibitor for the treatment of allergic rhinitis. It has completed Phase I/II clinical studies and is currently in Phase III clinical trials. Its developer, PrimeGene Therapeutics, is a biotechnology company focused on immune-inflammatory diseases and is currently pursuing an initial public offering on the Hong Kong Stock Exchange.

A breakthrough in delivery technology is a prerequisite for the success of small nucleic acid drugs. The focus of this collaboration lies in the announcement by SanegeneBio and Genentech that they will jointly advance the development of an RNAi therapeutic based on SanegeneBio's proprietary RNAi drug discovery platform. Currently, SanegeneBio possesses a self-developed GalNAc liver-targeted delivery platform and a proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) extrahepatic delivery platform.

Partial reprogramming technology has demonstrated significant potential in the field of anti-aging, yet safety concerns remain a persistent "ghost" hindering its clinical translation. Conventional transcription factors are prone to triggering uncontrolled gene activation during reprogramming, a risk often rooted in their intrinsic physical properties.

This contest marked the world's first head-to-head event in which a microsurgical robot performed live-animal vascular anastomosis against surgeons using manual techniques, setting an exceptionally high bar for participating robotic systems. After rigorous selection, FUNZAR emerged as the sole robotic device to qualify for the finals, where it competed head-to-head with the champion of the manual surgery group.

Preliminary statistics from VCBeat tracked 7 financing events in China's healthcare sector between January 26 and 30, 2026 (excluding IPOs and private placements). The period was led by SciBrunch's USD 35 million Series Pre-A round, followed by NeuShen Therapeutics' Series A+ round which raised tens of millions of US dollars.

DIP has successfully established the industry's first brain-science-based autonomous multi-agent ecosystem, known as the Synaptic Agent Ecosystem. This marks a shift from tool-oriented AI to an adaptive, decentralized, and self-evolving AI brain. DIP is continuously nurturing an autonomous agent neural network that operates like a biological brain, with its execution layer continuously accumulating practical experience to feed back and enrich its decision-making layer.

On January 30, CSPC Pharmaceutical and AstraZeneca have entered into a strategic collaboration and license agreement with a potential total value of $18.5 billion to develop innovative long-acting peptide medicines. The partnership will leverage CSPC's proprietary sustained-release delivery technology and AI-driven peptide discovery platforms.

Among the transaction's projects, the product involved in the collaboration and licensing between CSPC Megalith Biopharmaceutical and AstraZeneca primarily relates to an innovative peptide molecule along with related technologies and products, currently in the preclinical research stage. It aims to provide a longer-lasting treatment solution for individuals with obesity and weight-related concerns. Furthermore, there exists the possibility for CSPC Megalith Biopharmaceutical and AstraZeneca to engage in strategic collaboration on other related projects in the fields of innovative peptide molecule discovery and long-acting delivery product development.

Accelerating the clinical development of the core pipeline asset SPR1020. As a next-generation, highly selective Parp1 inhibitor with demonstrated brain-penetrant properties, SPR1020 achieved its first patient dosing on January 8, 2026.

As a high-tech enterprise specializing in electric vacuum technology in China, Eden Technologies has distinguished itself in the wave of domestic substitution for core components of high-end medical equipment. Leveraging the founder's top-tier industry expertise, the exceptional performance of its products, and its rapid commercialization capabilities, Eden Technologies has successfully addressed the critical "chokepoint" challenge related to CT bulb technology.

China's first self-developed next-generation TRK inhibitor, Zurletrectinib (brand name: Yinuoxin®), was approved for marketing, indicated for the treatment of adult and adolescent patients (12 years and older) with solid tumors harboring NTRK gene fusions.